Draft pharma policy hikes price control turnover limit to Rs.20 croreIllustrative image – not actual.

The draft pharmaceutical policy 2001 has recommended price control on bulk drugs with a turnover of over Rs.20 crore and 50 per cent market share. This is significantly higher than the earlier limit of Rs.4 crore.

 

In case of drugs with turnover of between Rs.5 crore and Rs.20 crore, a 90 per cent share with a single formulator would invite price controls.

 

The policy also proposes to remove the provision of limiting the profitability of pharmaceutical companies. Currently, the National Pharmaceutical Pricing Authority (NPPA) specifies the maximum allowable profit margin that a company can make on the basis of its turnover.

 

The draft also specifies that in case of drugs which are not included in the price control list, but are part of the essential drug list, or are used in national health programmes, the NPPA would monitor the price movement and consumption pattern.

 

The draft has kept the maximum allowable post manufacturing expenses (MAPE) for indigenously manufactured formulations at 100 per cent as against the Drug Price Control Review Committee’s recommendation to raise the limit to 130 per cent.

 

For imported formulations, a maximum of 50 per cent margin on landed cost to cover selling and distribution expenses, including interest and importers’ profit, would be allowed.

 

The draft policy also proposes that research and development-intensive companies who have achieved the 'gold standard', should qualify for an additional cost of 5 per cent of ex-factory cost in determination of prices of scheduled formulations manufactured by them.

 

Exemption from price control would be provided for a 15-year period to manufacturers producing new drugs developed through indigenous R&D.

 

Drugs and new delivery systems patented under the Indian Patents Act, 1970, would also be eligible for exemption from price control till the expiry of the patent.

 

In addition, any formulator who can present proof that the per-day cost to consumer of a drug is not more than Rs.2, will be exempt from price control.

 

The policy also states that the NPPA would have to be revamped and reoriented in order to develop an effective monitoring and enforcement system and to move away from the controlled regime to the monitoring regime.

← All latest storiesBack to top →